EuroapiFRA:940 +4.13%61 EBITDA Margin % is 0.87% as of Dec. 2025, which is 87% below its 10-year median of 6.52. GuruFocus rates FRA:940 with a GF Score™ of 61/100 and a GF Value™ of €2.91 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Euroapi ranks worse than 74.35% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Euroapi's EBITDA for the
six
months ended in Dec. 2025 was €3.8 Mil. Euroapi's Revenue for the
six
months ended in Dec. 2025 was €438.1 Mil. Therefore, Euroapi's EBITDA margin for the quarter that ended in Dec. 2025 was 0.87%.
Euroapi (FRA:940) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Euroapi EBITDA Margin % Related Terms
Euroapi EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Euroapi's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:940 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euroapi EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euroapi's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Euroapi's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euroapi (FRA:940) has a EBITDA Margin % of 0.87% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Euroapi and its competitors. This is 87% below median its historical median of 6.52. According to the industry distribution chart, Euroapi ranks #710 out of 955 companies in the Drug Manufacturers industry, placing it in the top 74.3%.
Is Euroapi's EBITDA Margin % too high?
Euroapi's current EBITDA Margin % of 0.87% is 87% below median its 10-year median of 6.52. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Euroapi's value of 0.87% is 93% below this industry median. Based on the distribution chart, Euroapi ranks #710 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Euroapi has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #710 out of 955 companies for EBITDA Margin %. This places Euroapi in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Euroapi's value of 0.87% is 93% below this benchmark. While the company's 10-year median is 6.52 vs. the industry median of 12.44, Euroapi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euroapi's current EBITDA Margin % of 0.87% is 93% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Euroapi and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current EBITDA Margin % is 0.87%, which is 87% below median its own 10-year median of 6.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (FRA:940) is currently considered Possible Value Trap. The stock's GF Value™ is €2.91, compared to a current price of €1.31 — trading 55% below its estimated fair value. The current EBITDA Margin % is 0.87%, which is 87% below median its 10-year median of 6.52 and 93% below the Drug Manufacturers industry median of 12.44. Euroapi's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Euroapi (FRA:940), the current EBITDA Margin % is 0.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euroapi (FRA:940) Overvalued in 2026?
Based on GuruFocus' analysis, Euroapi stock appears to be undervalued.
The current stock price of €1.31 is trading 55% below its estimated GF Value™ of €2.91.
GuruFocus considers Euroapi to be Possible Value Trap.
Key valuation signals for FRA:940:
EBITDA Margin %: 0.87% (87% below median its 10-year median of 6.52)
GF Value™: €2.91 vs. price of €1.31 (55% below fair value)
Industry Position: 93% below the Drug Manufacturers median (#710 of 955)
No single metric tells the full story. See the FRA:940 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
61GF Score
Get the complete analysis for FRA:940
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:940 has been successfully added to your 
